Edition:
India

Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

141.03USD
1:32am IST
Change (% chg)

$-5.70 (-3.88%)
Prev Close
$146.73
Open
$145.45
Day's High
$146.25
Day's Low
$140.78
Volume
94,729
Avg. Vol
104,802
52-wk High
$147.68
52-wk Low
$101.58

Latest Key Developments (Source: Significant Developments)

Charles River Labs Announces Fourth-Quarter And Full-Year 2018 Results
Wednesday, 13 Feb 2019 

Feb 13 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS AND PROVIDES 2019 GUIDANCE.Q4 NON-GAAP EARNINGS PER SHARE $1.49.Q4 GAAP EARNINGS PER SHARE $1.21.Q4 REVENUE $601.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $590.8 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $1.40 -- REFINITIV IBES DATA.SEES 2019 GUIDANCE, EXCLUDING CITOXLAB, GAAP EPS $5.05-$5.20.SEES 2019 GUIDANCE, EXCLUDING CITOXLAB, NON-GAAP EPS $6.25-$6.40.SEES 2019 REPORTED REVENUE GROWTH EXCLUDING CITOXLAB OF10.5% - 12.0%.SEES 2019 GUIDANCE, EXCLUDING CITOXLAB,FREE CASH FLOW $320- $330 MILLION.FY2019 EARNINGS PER SHARE VIEW $6.34 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $2.49 BILLION -- REFINITIV IBES DATA.  Full Article

Charles River Laboratories Signs Binding Offer To Acquire Citoxlab
Wednesday, 13 Feb 2019 

Feb 13 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES SIGNS BINDING OFFER TO ACQUIRE CITOXLAB.TRANSACTION EXPECTED TO BE ACCRETIVE TO NON-GAAP EPS BY APPROXIMATELY $0.15 IN 2019.DEAL FOR EUR 448 MILLION IN CASH (OR APPROXIMATELY $510 MILLION BASED ON CURRENT EXCHANGE RATES).SIGNED A BINDING OFFER TO ACQUIRE CITOXLAB FOR EUR 448 MILLION IN CASH.PROPOSED ACQUISITION IS EXPECTED TO ADD $115 TO $130 MILLION TO CHARLES RIVER'S 2019 CONSOLIDATED REVENUE.CHARLES RIVER LABORATORIES INTERNATIONAL - PROPOSED DEAL, FEES EXPECTED TO BE FINANCED THROUGH EXISTING REVOLVING CREDIT FACILITY AND CASH.PROPOSED ACQUISITION IS EXPECTED TO ADD APPROXIMATELY $200 MILLION TO 2020 CONSOLIDATED REVENUE.CHARLES RIVER LABORATORIES INTERNATIONAL- DEAL EXPECTED TO BE ACCRETIVE TO NON-GAAP EARNINGS PER SHARE BY ABOUT $0.15 IN 2019 AND AT LEAST $0.35 IN 2020.  Full Article

Atomwise, Charles River Laboratories Form Strategic Alliance
Friday, 11 Jan 2019 

Jan 11 (Reuters) - Atomwise::ATOMWISE AND CHARLES RIVER LABORATORIES FORM A STRATEGIC ALLIANCE TO PROVIDE PREMIER ARTIFICIAL INTELLIGENCE-POWERED DRUG DISCOVERY CAPABILITIES.ATOMWISE - UNDER DEAL, CO TO SUPPORT HIT DISCOVERY, HIT-TO-LEAD, LEAD OPTIMIZATION EFFORTS; CO TO MAKE TECHNOLOGY AVAILABLE FOR MULTIPLE PROJECTS.ATOMWISE - PROJECTS THAT TOTAL POTENTIAL VALUE OF ROYALTIES TO CO WITH SUCCESS IN ALL PROJECTS COULD EXCEED $2.4 BILLION.ATOMWISE - UNDER DEAL, CO TO GET TECHNOLOGY ACCESS FEES, MILESTONE-BASED PAYMENTS & ROYALTIES FROM CLIENTS.  Full Article

Charles River Laboratories Reports Q3 Adj. EPS of $1.53
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Charles River Laboratories International Inc ::ANNOUNCES THIRD-QUARTER 2018 RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $1.53.Q3 GAAP EARNINGS PER SHARE $1.22.Q3 REVENUE $585.3 MILLION VERSUS I/B/E/S VIEW $567.8 MILLION.Q3 EARNINGS PER SHARE VIEW $1.38 -- THOMSON REUTERS I/B/E/S.INTERNATIONAL INC - UPDATES 2018 GUIDANCE.INTERNATIONAL INC SEES FY 2018 GAAP EPS $4.44 - $4.54.INTERNATIONAL INC SEES FY 2018 NON-GAAP EPS $5.87 - $5.97.  Full Article

Charles River Laboratories Announces First-Quarter 2018 Results From Continuing Operations
Thursday, 10 May 2018 

May 10 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ANNOUNCES FIRST-QUARTER 2018 RESULTS FROM CONTINUING OPERATIONS.Q1 NON-GAAP EARNINGS PER SHARE $1.38.Q1 GAAP EARNINGS PER SHARE $1.08.Q1 REVENUE $494 MILLION VERSUS I/B/E/S VIEW $480.3 MILLION.Q1 EARNINGS PER SHARE VIEW $1.26 -- THOMSON REUTERS I/B/E/S.UPDATES 2018 GUIDANCE.REAFFIRMING ITS ORGANIC REVENUE GROWTH GUIDANCE FOR 2018..IS INCREASING 2018 GUIDANCE FOR REPORTED REVENUE GROWTH.IS INCREASING ITS NON-GAAP EARNINGS PER SHARE GUIDANCE FOR 2018.SEES 2018 NON-GAAP EPS $5.77 - $5.92.SEES 2018 REVENUE GROWTH, REPORTED 18% - 20%.SEES 2018 GAAP EPS $4.22-$4.37.CHARLES RIVER LABORATORIES INTERNATIONAL - 2018 EARNINGS PER SHARE GUIDANCE OF $4.22 TO $4.37 INCLUDES MPI RESEARCH DEAL.FY2018 EARNINGS PER SHARE VIEW $5.76, REVENUE VIEW $2.18 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Charles River Laboratories Reports Q1 Non-GAAP Earnings Per Share Of $1.38
Thursday, 10 May 2018 

May 10 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ANNOUNCES FIRST-QUARTER 2018 RESULTS FROM CONTINUING OPERATIONS.Q1 NON-GAAP EARNINGS PER SHARE $1.38.Q1 GAAP EARNINGS PER SHARE $1.08.Q1 REVENUE $494 MILLION VERSUS I/B/E/S VIEW $480.3 MILLION.Q1 EARNINGS PER SHARE VIEW $1.26 -- THOMSON REUTERS I/B/E/S.UPDATES 2018 GUIDANCE.REAFFIRMING ITS ORGANIC REVENUE GROWTH GUIDANCE FOR 2018..IS INCREASING 2018 GUIDANCE FOR REPORTED REVENUE GROWTH.IS PROVIDING INITIAL GAAP EARNINGS PER SHARE GUIDANCE INCLUDING ACQUISITION OF MPI RESEARCH OF $4.22 TO $4.37.IS INCREASING ITS NON-GAAP EARNINGS PER SHARE GUIDANCE FOR 2018.SEES 2018 NON-GAAP EPS $5.77 - $5.92.SEES 2018 REVENUE GROWTH, REPORTED 18% - 20%.SEES 2018 GAAP EPS $4.22-$4.37.FY2018 EARNINGS PER SHARE VIEW $5.76, REVENUE VIEW $2.18 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Charles River Laboratories Announces Offering Of $500 Mln Of Senior Notes
Monday, 26 Mar 2018 

March 26 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ANNOUNCES REFINANCING OF CREDIT FACILITIES AND OFFERING OF $500 MILLION OF SENIOR NOTES.CHARLES RIVER LABORATORIES - REFINANCED EXISTING $1 BILLION OF REVOLVING CREDIT FACILITY DUE 2021 WITH NEW $1.55 BILLION REVOLVING CREDIT FACILITY DUE 2023.CHARLES RIVER LABORATORIES - ALSO REFINANCED EXISTING $650 MILLION OF TERM LOAN FACILITY DUE 2021 WITH NEW $750.0 MILLION TERM LOAN FACILITY DUE 2023.CHARLES RIVER LABORATORIES - INTENDS TO OFFER $500 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF SENIOR NOTES DUE 2026 IN UNREGISTERED OFFERING.  Full Article

Charles River Laboratories Acquires KWS Biotest for GBP 15 Mln
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ACQUIRES KWS BIOTEST.CHARLES RIVER LABORATORIES ACQUIRES KWS BIOTEST.CHARLES RIVER LABORATORIES INTERNATIONAL INC - PURCHASE PRICE WAS APPROXIMATELY £15 MILLION IN CASH.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍ TRANSACTION INCLUDES A POTENTIAL ADDITIONAL PAYMENT OF UP TO £3 MILLION BASED ON FUTURE PERFORMANCE​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - TRANSACTION IS NOT EXPECTED TO BE MATERIAL TO 2018 GAAP OR NON-GAAP RESULTS FROM OPERATIONS.CHARLES RIVER LABORATORIES INTERNATIONAL INC - TRANSACTION IS NOT EXPECTED TO BE MATERIAL TO 2018 GAAP OR NON-GAAP RESULTS FROM OPERATIONS.  Full Article

Charles River Laboratories Says New Tax Legislation Expected To Be Effectively Neutral To Co's GAAP, Non-GAAP EPS In 2018
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES SAYS NEW TAX LEGISLATION EXPECTED TO BE EFFECTIVELY NEUTRAL TO CO'S GAAP AND NON-GAAP EPS IN 2018 - SEC FILING.  Full Article

Charles River Laboratories reports Q3 non-GAAP EPS of $1.30
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Charles River Laboratories International Inc ::Updates 2017 guidance​.Announces third-quarter 2017 results from continuing operations.Q3 non-GAAP earnings per share $1.30.Q3 GAAP earnings per share $1.09.Q3 revenue $464.2 million versus I/B/E/S view $458.7 million.Q3 earnings per share view $1.22 -- Thomson Reuters I/B/E/S.Sees ‍2017 revenue growth, reported 9.75 percent - 10.5 percent​.Sees ‍2017 non-GAAP EPS estimate $5.08 - $5.18​.Sees ‍2017 GAAP EPS estimate $3.95 - $4.05​.FY2017 earnings per share view $5.10, revenue view $1.85 billion -- Thomson Reuters I/B/E/S.  Full Article

Cancer center CEO leaves Merck board after disclosure scandal

NEW YORK The chief executive of Memorial Sloan Kettering Cancer Center, Craig Thompson, resigned from the boards of drugmaker Merck & Co Inc and lab services firm Charles River Laboratories International Inc on Tuesday, following media investigations about the U.S. center's ties to the pharmaceutical industry.